An Investigator-Initiated Study to Assess the Cooling Effect of Triamcinolone Acetonide Aerosol When Used for Steroid-Responsive Dermatoses
An Investigator-Initiated Study to Assess the Cooling Effect of Triamcinolone Acetonide Aerosol When Used for Steroid-Responsive Dermatoses
Triamcinolone acetonide is a mid-potency, class 4/5 topical corticosteroid that is available
 in a spray formulation (Triamcinolone Acetonide Spray, T Spray). It is indicated for the
 relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
 Unlike more potent steroid products, T Spray has no time limitations on its use; therefore,
 it is commonly used to treat flares in psoriasis, atopic dermatitis, seborrheic dermatitis,
 and contact dermatitis.

 In contrast to creams and ointments, T Spray can easily cover large and hard-to-reach areas
 of the body. Its optional nozzle directs application of the medication to precise areas
 without affecting nearby areas. Patients requiring a mid-potency corticosteroid for lesions
 on the scalp, back, intertriginous folds, large areas, or areas that require precise
 application would benefit from the T Spray formulation. In the time since the introduction of
 T Spray to dermatology, other topical corticosteroids have entered the market, but T Spray
 remains the only mid-potency corticosteroid available in a spray formulation.

 In a recently published open-label, non-comparator study involving 42 patients with chronic
 steroid-responsive dermatoses, T Spray was used up to four times a day for 28 days.
 Improvement of lesions after one week of treatment was experienced by 85% of patients, and
 95% of subjects preferred the spray over creams and ointment. Most importantly, 56% of
 patients reported an anti-pruritic cooling effect which was experienced upon application.
Inclusion Criteria:

 1. Subjects must be at least 18 years old and in good general health, as confirmed by a
 medical history

 2. A clear diagnosis of the chronic steroid-responsive dermatosis (i.e. psoriasis, atopic
 dermatitis) or acute steroid-responsive dermatosis (i.e. contact dermatitis,
 first-degree burn) must have been previously established and patients must have a
 target lesion that can be assessed for severity of inflammation

 3. Females of childbearing potential must have a negative urine pregnancy test to
 participate in the study

 4. Subjects must be able to understand the requirements of the study and sign an informed
 consent prior to study procedures

 Exclusion Criteria:

 1. Subjects who are pregnant and/or nursing

 2. Subjects with a known hypersensitivity to any component of the T Spray

 3. Subjects who are using any medication or have a disease which in the judgment of the
 investigator will interfere with the conduct or interpretation of the study

 4. Subjects with any of the following pathologies: cold urticaria, cryoglobulinemia,
 Raynaud's phenomena, or Paroxysmal cold hemoglobulinuria